Evidence map›Paper›PMID 35208698›Full record

ArticleMicroorganisms2022

Human-Based Immune Responsive In Vitro Infection Models for Validation of Novel TLR4 Antagonists Identified by Computational Discovery.

Helena Merk, Tehila Amran-Gealia, Doris Finkelmeier, Christina Kohl, Isabelle Pichota, Noa Stern, Steffen Rupp, Amiram Goldblum, Anke Burger-Kentischer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Helena MerkInstitute of Interfacial Process Engineering and Plasma Technology, University of Stuttgart, Nobelstr. 12, 70569 Stuttgart, Germany.
Tehila Amran-GealiaLaboratory of Molecular Modelling, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Doris FinkelmeierFraunhofer Institute of Interfacial Engineering and Biotechnology IGB, Nobelstr. 12, 70569 Stuttgart, Germany.
Christina KohlFraunhofer Institute of Interfacial Engineering and Biotechnology IGB, Nobelstr. 12, 70569 Stuttgart, Germany.
Isabelle PichotaFraunhofer Institute of Interfacial Engineering and Biotechnology IGB, Nobelstr. 12, 70569 Stuttgart, Germany.
Noa SternLaboratory of Molecular Modelling, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Steffen RuppInstitute of Interfacial Process Engineering and Plasma Technology, University of Stuttgart, Nobelstr. 12, 70569 Stuttgart, Germany.
Amiram GoldblumLaboratory of Molecular Modelling, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Anke Burger-KentischerFraunhofer Institute of Interfacial Engineering and Biotechnology IGB, Nobelstr. 12, 70569 Stuttgart, Germany.
Fraunhofer Institute for Interfacial Engineering and Biotechnology · DEHebrew University of Jerusalem · ILUniversity of Stuttgart · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious diseases are still a major problem worldwide. This includes microbial infections, with a constant increase in resistance to the current anti-infectives employed. Toll-like receptors (TLRs) perform a fundamental role in pathogen recognition and activation of the innate immune response. Promising new approaches to combat infections and inflammatory diseases involve modulation of the host immune system via TLR4. TLR4 and its co-receptors MD2 and CD14 are required for immune response to fungal and bacterial infection by recognition of microbial cell wall components, making it a prime target for drug development. To evaluate the efficacy of anti-infective compounds early on, we have developed a series of human-based immune responsive infection models, including immune responsive 3D-skin infection models for modeling fungal infections. By using computational methods: pharmacophore modeling and molecular docking, we identified a set of 46 potential modulators of TLR4, which were screened in several tests systems of increasing complexity, including immune responsive 3D-skin infection models. We could show a strong suppression of cytokine and chemokine response induced by lipopolysacharide (LPS) and

Indexed as

3D-immune-competent Infection modelsantagonistCandida albicansdockingpharmacophoreToll-like receptors

Identifiers

PMID35208698
PMCPMC8876567
OpenAlexW4214527367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.